Multiple Myeloma is:

- a rare blood cancer of the plasma cells
- the 2nd most common blood cancer in the US
- twice as commonly diagnosed among African Americans as White Americans

Statistics may present the reality – but they may not predict the future.

On average, it has taken Black Americans nearly 2X as long to start on modern therapies* compared to White Americans.

*Study assessed racial disparities in the treatment and outcomes of multiple myeloma. SEER Medicare 2013-2017 data base. 4820 total patients, 858 African American. Modern Therapies evaluated were immunomodulators and proteasome inhibitors.

LEARNING ABOUT MODERN THERAPIES IS ONE WAY TO EVEN THE ODDS

Find out more. Go to ICanEvenTheOdds.com.
From 2010 to 2016, over 50% of people lived five years past their diagnosis compared to roughly 35% of people in 1998. This is due to the approval of new effective treatments.

All things being equal.

Are you aware that African American patients in over a decade of national clinical trials for multiple myeloma had no statistically significant differences in response or survival rates from other patients?

For more information, it’s always best to talk to your doctor.

Do your research. Keep a positive mindset. Never bet against what you can do.